Network Bio
PrivateLast Round
Seed
Aug 19, 2026
Est. Valuation
$170M
Total Funding Raised
$67M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Network Bio operates in Healthcare & Life Sciences and is based in Austin, Texas. Its latest recorded funding round was a Seed round in August 2026.
Network Bio is a healthcare technology company that provides a clinical and molecular data library to facilitate precision medicine through the creation of research-grade data assets in concert with healthcare institutions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Data Warehousing
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Network Bio Comparables
Compare Network Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aster Insights | 79% | |
| Flat Iron | 79% | |
| Lifebit | 77% |
For institutional investors. Book with your work email.
Network Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 19, 2026 | ||||
| Seed | Feb 26, 2025 |
For institutional investors. Book with your work email.
Network Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Seed |
| Breyer Capital | Seed |
| Fundomo | Seed |
| Thiel Capital | Seed |
| JSL Health Capital | Seed |
| Founders Fund | Seed |
| ARTIS Ventures | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 19, 2026
Raised $50M with participation from Founders Fund and S32.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
Network is developing AI models designed to understand human biology using tissue, blood and clinical data for precision diagnostics, biomarker discovery and drug development in California.
- is_developingNov 9, 2026
Network enters a research collaboration with Duke University to develop artificial intelligence (AI) models of human disease using biospecimens and clinical records, with the resulting datasets intended to support earlier disease identification, therapeutic target discovery, and treatment matching.
- is_developingNov 9, 2026
Network partners with Duke University to develop AI-based models of human disease using biospecimens and clinical records in New York in Nov '26.
- is_developingOct 23, 2026
Network is developing bio-native AI designed to learn biological principles that transfer across diseases, tissues and data types.
- is_developingSep 9, 2026
Network is developing a bio-native AI architecture designed to analyze multimodal biological information across diseases, tissues and molecular data types.
For institutional investors. Book with your work email.
Network Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Network Bio's valuation, stock price, and market status.
Is Network Bio a public or private company?
Network Bio is a private company.
What is the current stock price of Network Bio?
Network Bio is a private company, so its shares have no public market price. Caplight tracks Network Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Network Bio worth (valuation)?
Network Bio's valuation is estimated at $170.0M based on funding round data.
Can I buy Network Bio stock?
Network Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Network Bio's last funding round?
Network Bio's most recent funding round was Seed on August 19, 2026.
Who are the main investors in Network Bio?
Key investors in Network Bio include S32, Breyer Capital, Fundomo, Thiel Capital, JSL Health Capital.
Will Network Bio IPO soon?
No public IPO plans have been announced for Network Bio.
How can I track Network Bio secondary market activity?
Caplight tracks bids, offers, and trades in Network Bio's shares on secondary markets.